Molecular biology of the lung cancer

Radiology and Oncology

Volumn 39, Issue 3, 2005, Pages

  Panov, Sasho Z ^a  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

Author keywords

Genes; Lung neoplasms genetics; Tumor suppressor

Indexed keywords

CARCINOGEN; COLLAPSIN RESPONSE MEDIATOR PROTEIN; CYCLIN B1; CYCLIN D1; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FRAGILE HISTIDINE TRIAD PROTEIN; GEFITINIB; INTEGRIN; LAMININ; MATRIX METALLOPROTEINASE; MESSENGER RNA; MICROSATELLITE DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN P14ARF; PROTEIN P19; PROTEIN P53; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; RETINOIC ACID RECEPTOR BETA; SOMATOMEDIN C RECEPTOR; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VASCULOTROPIN ANTIBODY;

CANCER GENETICS; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CAUSE OF DEATH; CLINICAL TRIAL; DNA MICROARRAY; DNA SEQUENCE; EPIGENETICS; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GROWTH STIMULATION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTASIS; METHYLATION; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE MYC; ONCOGENE N RAS; ONCOGENE NEU; ONCOGENE RAS; PROMOTER REGION; PROTO ONCOGENE; REVIEW; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 27644434949     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al; American Cancer Society. Cancer statistics, 2004. Cancer J Clin 2004; 54(1): 8-29.
2. Williams MD, Sandler AB. The epidemiology of lung cancer. Cancer Treat Res 2001; 105: 31-52.
3. Fong KM, Sekido Y, Gazdar AF, Minna JD. Lung cancer - 9. Molecular biology of lung cancer: clinical implications. Thorax 2003; 58: 892-900.
4. July LV, Beraldi E, So A, Fazli L, Evans K, English JC, et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 2004; 3(3): 223-32.
5. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Ins 1999; 91: 1194-210.
6. Dialyna IA, Miyakis S, Georgatou N, Spandidos DA. Genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes and lung cancer risk. Oncol Rep 2003; 10(6): 1829-35.
7. Gould MK, Silvestri GA, Detterbeck F. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350(19): 2008-10.
8. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98(24): 13790-5.
9. Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, Powell CA. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003; 163(5): 1949-60.
10. Meyerson M, Franklin WA, Kelley MJ. Molecular classification and molecular genetics of human lung cancer. Semin Oncol 2004; 31(1): 4-19.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
12. Massion PP, Carbone DP. The molecular basis of lung cancer: molecular abnormalities and therapeutic implications. Respiratory Research 2003; 4(1): 12-27.
13. Park IW, Wistuba II, Maitra A, Milchgrub S, Virmani AK, Minna JD, et al. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst. 1999; 91(21): 1863-8.
14. Geradts J, Fong KM, Zimmerman PV, Maynard R, Minna JD. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 1999; 5(4): 791-800.
15. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 2000; 60(17): 4894-906.
16. Zochbauer-Muller S, Gazdar AF, Minna JD. Molecular pathogenesis of lung cancer. Annu Rev Physiol 2002; 64: 681-708.
17. Keum JS, Kong G, Yang SC, Shin DH, Park SS, Lee JH, et al. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer 1999; 81(1): 127-32.
18. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 2000; 60(2): 242-4.
19. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000; 60(15): 4000-4.
20. Danesi R, de Braud F, Fogli S, de Pas TM, Di Paolo A, Curigliano G, etal. Pharmacogenetics of anti-cancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 2003; 55(1): 57-103.
21. Dowell JE, Minna JD. Chasing mutations in the epidermal growth factor in lung cancer. N Engl J Med 2005; 352(8): 830-2.
22. Rom WN, Hay JG, Lee TC, Jiang Y, Tchou-Wong KM. Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med 2000; 161(4 Pt 1): 1355-67.
23. Forgacs E, Zöchbauer-Müller S, Oláh E, Minna JD. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res 2001; 7(1): 6-13.
24. Johnson BE, Russell E, Simmons AM. MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. J Cell Biochem Suppl 1996; 24: 210-7.
25. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005; 92(1): 131-9.
26. Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 1995; 55(7): 1444-7.
27. Graziano SL, Gamble GP, Newman NB. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999; 17: 668-75.
28. Sethi T, Langdon S, Smyth J, Rozengurt E. Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Cancer Res 1992; 52(9 Suppl): 2737s-42s.
29. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000; 60(7): 1949-60.
30. Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 2002; 21(45): 6915-35.
31. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003; 10: 431-42.
32. Shackelford RE, Kaufmann WK, Paules RS. Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environ Health Perspect 1999; 107: 5-24.
33. Schulze-Bergkamen H, Krammer PH. Apoptosis in cancer - implications for therapy. Semin Oncol 2004; 31(1): 90-119.
34. Reed J. Double identity for proteins of the Bcl-2 family. Nature 1997; 387(6635): 773-6.
35. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281(5381): 1322-6.
36. Belka C, Budach W. Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology. Int J Radiat Biol 2002; 78 (8): 643-58.
37. Kaiser U, Schilli M, Haag U. Expression of bcl-2-protein in small cell lung cancer. Lung Cancer 1996; 15(1): 31-40.
38. Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2003; 89(1): 55-64.
39. Zakian V. Telomeres: beginning to understand the end. Science 1995; 270(5242): 1601-7.
40. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, et al. A highly conserved repetitive DNA sequence (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 1988; 85(18): 6622-6.
41. Wright WE, Tesmer VM, Huffman KE, Levene SD, Shay JW. Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev 1997; Ĺ 2801-9.
42. Harley C, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345(6274): 866-8.
43. Hahn WC. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 2003; 21(10): 2034-43.
44. sEvans SK, Lundblad V. Positive and negative regulation of telomerase access to the telomere. J Cell Sci 2000; 113 Pt 19: 3357-64.
45. Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer. J Cell Physiol 1999; 180(1): 10-8.
46. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 1999; 8(1): 137-42.
47. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet 2001; 10(7): 677-85.
48. Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, et al. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 1997; 89(21): 1609-15.
49. Lantuejoul S, Soria JC, Morat L, Lorimier P, Moro-Sibilot D, Sabatier L, et al. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions. Clin Cancer Res 2005; 11(5): 2074-82.
50. Fontanini G, Vignati S, Boldrini L. Vascular Endothelial Growth Factor Is Associated with Neovascularization and Influences Progression of Non-Small Cell Lung Carcinoma. Clin Cancer Res 1997; 3: 861-5.
51. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 1999; 24(2): 73-6.
52. Pecina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 2003; 3(1): 17.
53. Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, Brambilla E, et al. WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci USA 2003; 100(18): 10429-34.
54. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 2002; (1 Suppl 4): 78-86.
55. Shih JY, Yang SC, Hong TM, Yuan A, Chen JJ, Yu CJ, et al. Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J Natl Cancer Inst 2001; 93(18): 1392-400.
56. Raper JA. Semaphorins and their receptors in vertebrates and invertebrates. Curr Opin Neurobiol 2000; 10(1): 88-94.
57. Akashi T, Ito E, Eishi Y, Koike M, Nakamura K, Burgeson RE. Reduced expression of laminin alpha 3 and alpha 5 chains in non-small cell lung cancers. Jpn J Cancer Res 2001; 92(3): 293-301.
58. Manda R, Kohno T, Niki T, Yamada T, Takenoshita S, Kuwano H, et al. Differential expression of the LAMB3 and LAMC2 genes between small cell and non-small cell lung carcinomas. Biochem Biophys Res Commun 2000; 275(2): 440-5.
59. Hirsch FR, Franklin WA, Gazdar AF, Bunn PA Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 2001; 7(1): 5-22.